



G1 Therapeutics to Report Fourth Quarter and Full-Year 2018 Financial Results on February 28, 2019

February 21, 2019

RESEARCH TRIANGLE PARK, N.C., Feb. 21, 2019 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that it will host a webcast and conference call to report financial results for the fourth quarter and full-year 2018 on Thursday, February 28, 2019 at 4:30 p.m. ET.

The live call may be accessed by dialing 866-763-6020 (domestic) or 210-874-7713 (international) and entering the conference code: 2698949. A live and archived webcast will be available on the [Events & Presentations](#) page of the company's website: www.g1therapeutics.com.

G1 will provide an update on its clinical-stage oncology drug candidates at an Investor Day on March 6, 2019. The company will announce additional details on the event, including webcast information, on February 27.

About G1 Therapeutics

G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of innovative therapies that improve the lives of those affected by cancer. The company is advancing three clinical-stage programs, [trilaciclib](#), [lerociclib](#) and [G1T48](#), that are designed to enable more effective combination treatment strategies and improve patient outcomes across multiple oncology indications.

G1 is based in Research Triangle Park, NC. For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics.

Contact:

Jeff Macdonald
Head of Investor Relations/Public Relations
919-907-1944
jmacdonald@g1therapeutics.com



Source: G1 Therapeutics